ADAPTIVE BIOTECHNOLOGIES CORPORATION - COMMON STOC

Adaptive Biotechnologies Reports Fourth Quarter and Full Year 2023 Financial Results

14 2 2024 16:05:54 提供 Nasdaq GlobeNewswire

Adaptive Biotechnologies to Report Fourth Quarter and Full Year 2023 Financial Results on February 14, 2024

29 1 2024 16:05:00 提供 Nasdaq GlobeNewswire

Adaptive Biotechnologies to Present at the 42nd Annual J.P. Morgan Healthcare Conference

27 12 2023 16:05:00 提供 Nasdaq GlobeNewswire

Adaptive Biotechnologies Announces New Data Highlighting the Clinical Relevance of MRD Testing with clonoSEQ® in Patients with Blood Cancers at the 65th ASH Annual Meeting

09 12 2023 08:30:37 提供 Nasdaq GlobeNewswire

Adaptive Biotechnologies and Collaborators to Present More than 30 Abstracts Demonstrating the Actionability of clonoSEQ® MRD Testing in Blood Cancer Patient Care and Drug Development at the 65th ASH Annual Meeting

05 12 2023 07:30:38 提供 Nasdaq GlobeNewswire

Adaptive Biotechnologies Reports Third Quarter 2023 Financial Results and Provides Business Update

09 11 2023 16:05:00 提供 Nasdaq GlobeNewswire

Adaptive Biotechnologies Announces New Translational Collaboration to Measure Minimal Residual Disease with clonoSEQ® Assay Across BeiGene’s Lymphoid Malignancy Pipeline

07 11 2023 07:30:36 提供 Nasdaq GlobeNewswire

Adaptive Biotechnologies to Report Third Quarter Financial Results on November 9, 2023

02 11 2023 16:05:00 提供 Nasdaq GlobeNewswire

Adaptive Announces Launch of Epic Integration for clonoSEQ®

13 9 2023 07:30:49 提供 Nasdaq GlobeNewswire

Adaptive Biotechnologies to Participate in the Morgan Stanley 21st Annual Global Healthcare Conference

30 8 2023 16:30:00 提供 Nasdaq GlobeNewswire

Adaptive Biotechnologies Reports Second Quarter 2023 Financial Results

02 8 2023 16:05:54 提供 Nasdaq GlobeNewswire

Adaptive Biotechnologies to Report Second Quarter Financial Results on August 2, 2023

10 7 2023 16:05:00 提供 Nasdaq GlobeNewswire

Adaptive Biotechnologies Highlights New Data at ASCO 2023 and EHA 2023 Underscoring the clonoSEQ® Assay’s Impact as a Standard for Minimal Residual Disease Assessment in Patients with Hematologic Cancer

02 6 2023 07:34:30 提供 Nasdaq GlobeNewswire

Adaptive Biotechnologies to Participate in Upcoming June Investor Conferences

24 5 2023 16:05:00 提供 Nasdaq GlobeNewswire

Adaptive Biotechnologies to Participate in the 2023 RBC Capital Markets Global Healthcare Conference

12 5 2023 08:00:00 提供 Nasdaq GlobeNewswire

Adaptive Biotechnologies Announces FDA Acceptance of Genentech’s Investigational New Drug Application for the First Neoantigen-Directed T-Cell Therapy Product in Oncology

09 5 2023 07:30:35 提供 Nasdaq GlobeNewswire

Adaptive Biotechnologies Reports First Quarter 2023 Financial Results

03 5 2023 16:05:01 提供 Nasdaq GlobeNewswire

Adaptive Biotechnologies to Participate in the BofA Securities 2023 Healthcare Conference

25 4 2023 16:05:00 提供 Nasdaq GlobeNewswire

Adaptive Biotechnologies Announces Translational Collaboration with Takeda to Measure Minimal Residual Disease with Its clonoSEQ® Assay Across Its Hematologic Malignancy Pipeline

12 4 2023 07:30:43 提供 Nasdaq GlobeNewswire

Adaptive Biotechnologies to Report First Quarter Financial Results on May 3, 2023

06 4 2023 16:05:00 提供 Nasdaq GlobeNewswire